As the coronavirus pandemic rages on amid a severe economic crisis, the cannabis industry remains relatively strong. The controversial plant has grown immensely popular over the past few years, especially after researchers started looking into its purported medical abilities. Users say cannabis can be effective against a variety of ailments ranging from chronic pain and anxiety to fighting cancer and regulating and preventing diabetes, but only a few of these claims are backed by hard data. At the moment, it is nearly impossible for American researchers to study cannabis as it is still classified as a Schedule 1 substance.
Canada, on the other hand, has legalized both medical and recreational cannabis and researchers are free to study the effect of cannabis on human illness. In a bid to collect more hard data on cannabis, the University Health Network (“UHN”) in Canada is embarking on a six-month study to see whether there is any truth behind the claims that cannabis can help patients. Dubbed ‘The Medical Cannabis Real World Evidence Study,’ it is looking to enroll at least 2,000 people who have been prescribed medical marijuana to treat certain conditions including chronic pain, sleep anxiety, and depression.
Researchers will use a portal run by Canadian pharmacy retailer Shoppers Drug Mart which contains detailed and accurate information on the medical cannabis products it sells including oils, extracts, dried flower, topical preparations, and edibles. Participants will be required to select cannabis products from the portal and report on their effectiveness in treating their ailments. The nationwide study is the very first of its kind, and it will be led by UHN’s Dr. Hance Clarke, Director of Pain Services at Toronto General Hospital.
UHN will partner with a number of cannabis sellers to see how specific products affect certain ailments. Radient Technologies, a high-quality cannabinoid-based formulation, and products manufacturer will provide three oral spray formulations for the study participants.
“Radient strongly believes that consistency, safety, and standardization are key elements for all medical products, and are excited to partner with UHN, Shoppers, and TruTrace on this groundbreaking study,” says Radient Technologies CEO Denis Taschuk. “Providing patients and medical professionals with trusted products that deliver repeatable results is a crucial step in having cannabis incorporated into medical treatments and is at the heart of Radient products.”
“Shoppers is creating a standard for medical cannabis, which along with the data from these clinical trials, will increase the confidence of both doctors and patients in using cannabis for medical purposes,” the CEO added.
Industry watchers say sector players like Pac Roots Cannabis Corp. (CSE: PACR) will be eager to learn what data comes out of this first of a kind study.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.